




IRA THREATENS CURES FOR PATIENTS WITH ALZHEIMER'S, MULTIPLE SCLEROSIS AND MORE





Study Shows Government-Mandated Drug Pricing Policies Decimate Development of Medicine Combating Neurological Conditions

A new study by research firm Vital Transformation estimates that there would be hundreds of lost therapies, including those for patients undergoing treatment for neurological conditions like Alzheimer's, MS, ALS, lupus and epilepsy, if Congress expands new aggressive government-mandated drug pricing policies.

LOST THERAPIES	LOST INNOVATION
 <p>70% of all currently available medicines – treatments Americans rely on every day – would likely never have been created, including nearly a dozen different treatments for neurological conditions.</p>	 <p>237 fewer medicines will be FDA-approved over the next decade, especially in areas where we are desperately seeking cures – like neuromuscular conditions.</p>

"PILL PENALTY" LOOMS OVER NEUROLOGY PATIENTS' HOPE FOR A CURE

The new IRA law discourages the development of medicines that come in pill or tablet form, often referred to as "small molecule medicines." Small molecule drugs are used for most treatments for neurological conditions like Alzheimer's because they can cross the blood-brain barrier¹. In addition, they may be taken orally, which gives patients with mobility issues easier access to treatment and the ability to be treated at home instead of a healthcare delivery setting.

	IRA	WH BUDGET PROPOSAL & SENATE SMART PRICES ACT
 <p>Time Limit Between FDA Approval & Mandated Price</p>	<p>Small-molecule drugs 9 years</p> <p>Biologics 13 years</p>	 <p>All drugs 5 years</p>
<p>Mandating prices on medical discoveries so soon after they're approved will have a chilling effect on neurological disease research and development.</p>		

1. Mikitsh, John et al. "Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier." [National Library of Medicine](#), July 20, 2023.

IRA THREATENS CURES FOR PATIENTS WITH ALZHEIMER'S, MULTIPLE SCLEROSIS AND MORE



ACCELERATING ACCESS TO CRITICAL THERAPIES INITIATIVE DERAILED BY IRA CONSEQUENCES

In 2021, a bipartisan group of lawmakers passed the **Accelerating Access to Critical Therapies for ALS Act** into law², establishing a partnership led by the National Institutes of Health and the Food and Drug Administration, academic institutions, non-profits, and private businesses to accelerate the search for a cure to ALS and other neurodegenerative diseases. The IRA provisions directly interfere with the goal of the initiative, signed into law during President Biden's first year in office.



WHAT THEY'RE SAYING ABOUT CANCER INVESTMENTS

"This program [the Inflation Reduction Act] is bad for innovation—and, in turn, the millions of patients who are counting on the pharmaceutical industry to develop new treatments and cures that save lives and improve health and wellbeing."

– **Bristol Myers Squibb**³

"Other parts of the legislation [the Inflation Reduction Act] are likely to have highly detrimental impacts, particularly on the discovery and development of small molecule medicines which play an important role in treating cancer, neurological conditions, and many other diseases...Decades of research are culminating in new, life-changing treatments. But we are still on the cusp of the biggest breakthroughs. Tipping the scale away from small molecule drugs means tipping the scale away from critical research in devastating diseases – and, more importantly, patients."

– **Eli Lilly**⁴

LEARN MORE

The new study issued by We Work For Health (WWFH) and Vital Transformation modeled the impacts on industry revenues, jobs and future research and development investments. For the full study, please visit [We Work For Health](#).

2. H.R. 3537. 117th Congress (2021-2022), 2021, [Congress.gov](#).

3. "Impact of the Inflation Reduction Act on Innovative Medicines for Patients." [Bristol Myers Squibb](#), June 16, 2023.

4. "The Inflation Reduction Act's Impact on Drug Discovery and Development." [Eli Lilly](#), July 20, 2023.